Using a modified RNA building block to create new aptamers for better target recognition
8-Oxo-7,8-dihydroguanosine in aptamer development and its impact on RNA structure
This study is looking at a new way to create special RNA tools that can help doctors find and treat diseases better, using a modified building block to make them more effective, which could lead to improved tests and treatments for patients.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-10652174 on NIH RePORTER |
What this research studies
This research focuses on developing new RNA aptamers using a modified building block called 8-oxo-7,8-dihydroguanosine (8-oxoG). By incorporating this modification, the researchers aim to enhance the specificity and recognition capabilities of aptamers, which are important tools in diagnostics and therapeutics. The project will explore how 8-oxoG affects RNA structure and stability, and how these modified aptamers can be used to select metabolites of interest. Patients may benefit from advancements in diagnostic tools and targeted therapies that arise from this innovative approach.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research include individuals with conditions that could be diagnosed or treated using advanced aptamer technologies.
Not a fit: Patients with conditions unrelated to the applications of aptamers or those not requiring diagnostic advancements may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved diagnostic tools and targeted therapies for various diseases.
How similar studies have performed: Previous research has shown promise in using modified nucleobases for enhancing aptamer functionality, indicating a potential for success in this novel approach.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Resendiz, Marino Je — University of Colorado Denver
- Study coordinator: Resendiz, Marino Je
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.